Ovid Therapeutics (OVID) Competitors

Ovid Therapeutics (NASDAQ:OVID) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.

Which has more risk & volatility, OVID or FULC?

Ovid Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500.

Which has higher earnings and valuation, OVID or FULC?

Ovid Therapeutics has higher earnings, but lower revenue than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$390K	134.74	-$52.34M	-$0.47	-1.57
Fulcrum Therapeutics	$2.81M	76.02	-$97.33M	-$0.31	-12.77

Does the media prefer OVID or FULC?

In the previous week, Ovid Therapeutics and Ovid Therapeutics both had 1 articles in the media. Fulcrum Therapeutics' average media sentiment score of 1.81 beat Ovid Therapeutics' score of 1.46 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Does the MarketBeat Community believe in OVID or FULC?

Ovid Therapeutics received 256 more outperform votes than Fulcrum Therapeutics when rated by MarketBeat users. Likewise, 70.80% of users gave Ovid Therapeutics an outperform vote while only 61.25% of users gave Fulcrum Therapeutics an outperform vote.

Company	Underperform	Outperform
Ovid Therapeutics	Outperform Votes 354 70.80%	Underperform Votes 146 29.20%
Fulcrum Therapeutics	Outperform Votes 98 61.25%	Underperform Votes 62 38.75%

Do institutionals & insiders hold more shares of OVID or FULC?

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 13.3% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is OVID or FULC more profitable?

Fulcrum Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -5,142.56%. Fulcrum Therapeutics' return on equity of -7.31% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-5,142.56%	-39.24%	-26.19%
Fulcrum Therapeutics	N/A	-7.31%	-6.74%

Do analysts recommend OVID or FULC?

Ovid Therapeutics currently has a consensus target price of $4.04, indicating a potential upside of 445.95%. Fulcrum Therapeutics has a consensus target price of $9.33, indicating a potential upside of 135.69%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
Fulcrum Therapeutics	1 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Ovid Therapeutics beats Fulcrum Therapeutics on 10 of the 18 factors compared between the two stocks.